Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827618 · ClinicalTrials.gov registry record · Early Phase 1
Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 29
- Enrollment target
NCT01827618 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 29 participants.
The verdict
NCT01827618, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study aims to evaluate the effects of rapamycin directly on bladder tumors and the effects of rapamycin on the immune system of patients with bladder cancer.
Interventions
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827618
The ClinicalTrials.gov registry entry for NCT01827618 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapamycin is the first listed.
NCT01827618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01827618 about?
NCT01827618 is a clinical study titled "Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy". This study aims to evaluate the effects of rapamycin directly on bladder tumors and the effects of rapamycin on the immune system of patients with bladder cancer.
What is the current status of trial NCT01827618?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2012-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01827618?
The interventions under investigation include: Rapamycin (DRUG).
Who is sponsoring clinical trial NCT01827618?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.